Imjudo (tremelimumab) / Pfizer, AstraZeneca  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
NCT00584493: Treatment Use Study for Advanced Melanoma.

No Longer Available
N/A
US
CP-675,206
Pfizer
Advanced Unresectable Melanoma
 
 
MITRE, NCT04107168: Microbiome Immunotherapy Toxicity and Response Evaluation

Recruiting
N/A
1800
Europe
Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin
CCTU- Cancer Theme, Microbiotica Ltd
Melanoma, Renal Cancer, Lung Cancer
07/24
07/25
NCT05667064: Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Recruiting
N/A
300
Japan
AstraZeneca
Unresectable Hepatocellular Carcinoma
12/26
12/26
NCT05826366: Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Active, not recruiting
N/A
296
Japan
AstraZeneca
Carcinoma, Non-Small-Cell Lung
11/25
11/25
REFINE-IO, NCT06117891: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Recruiting
N/A
300
Europe, US, RoW
Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab,
Bayer
Unresectable Hepatocellular Carcinoma
11/26
02/27

Download Options